Company News Press Release ClearNote Health Avantect® Pancreatic Cancer Test Enters Patient Enrollment Phase of Groundbreaking UK Study Targeting High-Risk Patients cnhnewcorpdev June 16, 2025
Company News Press Release ClearNote Health to Showcase Latest Advancements in Tumor Subtyping and Circulating Tumor Fraction Technologies at AACR Annual Meeting 2025 cnhnewcorpdev April 23, 2025
Company News Press Release ClearNote Health’s Avantect® Pancreatic Cancer Test Now Available to Health Plan Members Accessing Claritev’s National PPO Networks cnhnewcorpdev March 12, 2025
Company News Press Release ClearNote Health Earns Approval for Avantect® Pancreatic Cancer Test from New York State Department of Health cnhnewcorpdev February 18, 2025
Company News Press Release ClearNote Health’s Avantect® Multi-Cancer Detection Test Selected as One of Two Noninvasive Blood-Based Technologies for National Cancer Institute’s Vanguard Study cnhnewcorpdev January 7, 2025
Press Release ClearNote Health’s Avantect® Test Selected for World’s Largest Study of Pancreatic Cancer Detection in High-Risk Patient Population ClearNote Health December 18, 2024
Press Release Avantect Pancreatic Cancer Test Cost-Effective When Used as a Surveillance Tool in High-Risk Patients Newly Diagnosed with Diabetes ClearNote Health October 31, 2024
Press Release Avantect Ovarian Cancer Test Receives CPT Code and Preliminary Payment Determination from the Centers for Medicare and Medicaid Services ClearNote Health September 26, 2024
Press Release New Data Show ClearNote Health’s Epigenomic Platform Provides a Novel Tissue-Free, Liquid Biopsy-Based Approach to Identify Potential Predictive Biomarker Candidates to Radioligand Therapy Response in Patients With Pancreatic Neuroendocrine Tumors ClearNote Health March 26, 2024
Press Release Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology ClearNote Health January 30, 2024
